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Purpose: Lipid oxidation has been proposed to be a factor in the pathophysiology of glaucoma. We investigated whether
elevated  levels  of  isolevuglandin  (iso[4]LGE2)  protein  adducts  are  associated  with  astrocytes  derived  from  the
glaucomatous optic nerve head. In addition, we examined whether the iso[4]LGE2 protein adducts are altered following
exposure of astrocytes to elevated pressure.
Methods: Astrocytes were isolated from rat brain cortex and human optic nerve and were subjected to pressure treatments,
western blot analyses, liquid chromatography tandem mass spectrometry, and immunocytochemistry.
Results: Elevated levels of isolevuglandin (iso[4]LGE2) protein adducts were associated with astrocytes derived from the
glaucomatous (n=10) optic nerve head when compared to those from controls (n=6). Astrocytes subjected to in vitro
pressure treatment resulted in increased levels of iso[4]LGE2 protein adducts. Pressure exposure and the recovery period
affect iso[4]LGE2 protein modification, and pyridoxamine was effective in decreasing the appearance of iso[4]LGE2
protein adduct immunoreactivity when applied immediately after pressure treatment.
Conclusions:  These  results  suggest  that  the  elevated  iso[4]LGE2  protein  adduct  immunoreactivity  observed  in
glaucomatous astrocytes may be due to chronic and/or prolonged exposure to pressure, and pyridoxamine may have
prophylactic utility against such oxidative protein modification.
Primary open-angle glaucoma (POAG), a leading cause
of blindness worldwide [1,2], is a progressive and irreversible
disorder that is often accompanied by increased intraocular
pressure  (IOP)  and  characterized  by  optic  nerve  damage.
Elevated IOP leads to damage of the axons of retinal ganglion
cells and is responsible for their death. The initial site of optic
nerve damage is believed to be the lamina cribrosa [3,4].
Changes in the damaged optic nerve head (ONH) involve
several cell types including neurons and surrounding glial
cells. Glial cells in the central nervous system (CNS) are
divided  into  three  major  types:  astrocytes,  microglia,  and
oligodendrocytes [5]. The astrocytes, oligodendrocytes, and
microglias protect the neurons from damage and have other
supportive functions. Following injury to the CNS, the glial
cells undergo activation and initiate repair processes.
Previous studies recorded changes in morphology as well
as modulation of several molecules in response to an increase
in  hydrostatic  pressure.  For  example,  increased  adenylyl
cyclase activity [6], nitric oxide synthase 2 [7], elastin [8], and
Neural cell adhesion molecule (NCAM) [9] were found to be
upregulated in astrocytes from the optic nerve head and in
parallel, in vitro in response to hydrostatic pressure.
Intraocular pressure is known to affect different cell types
in the optic nerve head [10]. The median normal intraocular
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pressure in the eye is about 16.5 mmHg [11]. The average
intraocular  pressure  in  POAG  patients  is  amazingly  only
about 23–24 mmHg with around 30% having a pressure that
is  in  the  statistically  normal  range  (21  mmHg  or  less)
[12-14]. It is not unusual to have an untreated pressure near
30 or 40 mmHg often in relatively young patients of pigment
dispersion, pseudoexfoliation, or glaucoma that results from
other causes. Nevertheless, in some cases of glaucoma, the
arterial supply to the ciliary body is obstructed when the
pressure reaches a level near 60 or 70 mmHg. At this pressure,
the eye cannot make any aqueous humor, and the pressure
ceases to rise to a higher level. In a few cases of people with
high  blood  pressure,  the  intraocular  pressure  may  reach
80 mmHg if the arterial pressure is high enough to keep the
ciliary body nourished, but the maximum that can be achieved
is  around  60–70  mmHg  (personal  communication,  Dr.
Douglas Anderson, Bascom Palmer Eye Institute, Miami, FL)
[12,13]. This contrasts with brain injury in which very high
pressure  is  occasionally  experienced  by  cells  including
astrocytes [15]. Previously, in studies that model brain injury,
astrocytes were subjected to very high pressures, often more
than  five  times  that  of  atmospheric  pressure  for  a  short
duration [16].
Oxidative  stress  has  been  implicated  as  an  important
factor influencing neurodegenerative diseases [17,18]. The
eye and the brain are known to consume large amounts of
oxygen that often exceed their antioxidant defense systems,
resulting  in  the  generation  of  free  radicals  and  causing
elevation  in  levels  of  oxidative  stress.  Reactive  oxygen
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1079species (ROS) produced from the respiratory chain in the
mitochondria are largely responsible for oxidative stress in the
eye and brain [19,20].
The elevated levels of oxidative stress in the eye and brain
also make them likely targets for lipid peroxidation due to the
presence  of  very  high  levels  of  lipids  that  incorporate
arachidonic and docosahexaenoic acids [21-23]. Arachidonic
acid  was  detected  in  the  bovine  optic  nerve  [24,25].
Isolevuglandins are produced by free radical oxidation of
arachidonic acid (Figure 1) by the isoprostane pathway [26].
They  are  highly  reactive  γ-ketoaldehydes  capable  of
adduction to lysine residues of proteins to form Schiff’s base
adducts. Isolevuglandins have been implicated in neurologic
disorders such as Alzheimer disease [27], multiple sclerosis
[28], amyotrophic lateral sclerosis [29], and in glaucoma [30,
31].  Previously,  we  demonstrated  protein  modification  in
glaucomatous ocular tissues by lipid peroxidation products
including  specific  modification  with  an  isolevuglandin,
iso[4]LGE2 [30,31].
Astrocytes provide metabolic factors to the neurons and
also  help  in  the  clearance  of  neuronal  excretory  products
[32]. In POAG, astrocytes in the ONH are often exposed to
elevated pressure due to elevation of IOP. Similarly, in many
traumatic brain injuries, astrocytes are exposed to abnormally
elevated pressure as well [16]. Pressure gradients have been
proposed  to  play  a  major  role  in  neuronal  injury  [33].
Following injury to the CNS, quiescent astrocytes become
activated [34] and secrete growth factors and cell adhesion
molecules  such  as  platelet  derived  growth  factor,  several
different proteoglycans, glial fibrillary acidic protein (GFAP),
and  vimentin  [35,36].  Reactive  astrocytes  have  been
implicated  in  several  neurodegenerative  disorders  such  as
Alzheimer and Parkinson [37,38] and in glaucomatous optic
neuropathy [34]. Astrocytes migrate to the site of the damaged
optic  nerve  in  glaucomatous  neuropathy  and  produce
neurotoxic factors such as nitric oxide and tumor necrosis
factor alpha [39,40]. Astrocytes but not neurons possess the
capacity to synthesize arachidonic and docosahexaenoic acids
[41].
Figure 1. Schematic representation of
isolevuglandins (isoLGs) generated by
free  radical-induced  oxidation  of
arachidonates.  Arachidonates  such  as
AA-PC  are  efficiently  trapped  by
pyridoxamine,  preventing  their
adduction to proteins.
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1080The specific occurrence of iso[4]LGE2-modified proteins
in astrocytes derived from glaucomatous eyes or CNS tissue
exposed to over-pressure have not been investigated. Our
initial  analyses  did  not  show  a  discernable  difference  in
iso[4]LGE2 protein adduct immunoreactivity between control
and glaucomatous optic nerve tissues. This is in contrast to the
trabecular meshwork (TM) where a significant difference in
iso[4]LGE2  protein  adduct  immunoreactivity  was  found
between control and glaucomatous tissues [30,31].
We now present evidence that lipid oxidation products
(iso[4]LGE2-modified  proteins)  are  present  in  astrocytes
derived  from  glaucomatous  ONH.  In  addition,  astrocytes
subjected  to  pressure  treatment  develop  iso[4]LGE2
modifications in vitro that may provide insight into the in vivo
modification  events.  We  further  demonstrate  that
pyridoxamine, a pharmacological agent and known inhibitor
of iso[4]LGE2 formation [42], can protect astrocyte proteins
against  modification  by  iso[4]LGE2,  which  is  generated
endogenously upon pressure treatment.
METHODS
Isolation of astrocytes and pressure treatment: Astrocytes
were obtained either from the human optic nerve or from rat
brain  cortex  tissue.  For  human  ONH  astrocytes,  cadaver
donors were procured. All donor eyes were from Caucasian
individuals  (except  one  Asian  66-year-old  female
glaucomatous donor) from either gender who were subjected
to enucleation within 12 h of death following the Tenets of
Helsinki using previously described methods [30,43]. The
donor eyes were received from donors of two age groups,
7−10 years old for one group and 54−84 years old for the other
group. Donor eyes for these experiments were procured from
the  National  Disease  Research  Interchange  (Philadelphia,
PA), Florida Lions Eye Bank, Miami, FL, and the Cleveland
Eye Bank (Cleveland, OH). Astrocytes were also obtained
from  the  brain  cortex  of  Sprague  Dawley  rats  (Harlan,
Indianapolis, IN), from postnatal day 3 (P3) pups and enriched
at 99% purity following previously published protocols [44].
Cells from rats were procured following the approval of the
Institutional  Animal  Care  and  Use  Committee,  and  the
procurement adhered to the tenets of the ARVO statement.
Briefly,  the  cerebrum  was  removed  under  a  dissection
microscope  and  placed  in  Hank's  Buffered  Salt  Solution
(HBSS)  buffer  containing  1%  penicillin/streptomycin/
amphoterecin  (Invitrogen  Inc.,  Carlsbad,  CA).  The  mixed
glial cell suspensions were grown on 75 cm plates coated with
5 µg/ml poly-l-lysine (Sigma Chemical Co., St. Louis, MO)
in Dulbecco’s modified Eagle’s medium (DMEM) containing
10%  fetal  bovine  serum  (FBS)  and  penicillin  and
streptomycin [45]. From these mixed cell suspensions, C5-
positive cells were obtained using immunopanning [46]. Cells
were subsequently cultured in Ham’s F-10 medium with 8%
FBS, subjected to passage with a 0.25% trypsin solution, and
subsequently plated in a serum-free astrocyte growth medium
(AGM) [47]. After 24 h in culture, the medium was changed
to AGM containing 5% FBS. The majority of the cells that
attached  in  the  serum-free  medium  were  astrocytes.
Sequential panning was adopted to further purify astrocytes.
Briefly, the cell suspension of primary cells was panned first
on a Petri dish coated with C5 monoclonal antibody to select
for cells of astrocyte lineage using multiple rounds of C5
based cell enrichment through immunopanning [46].
Change to: Isolated astrocytes were plated on 15 mm
culture plates and subjected to pressure in a sealed pressure
chamber [44,48] for pressure and duration as indicated in each
individual  experiment.  After  pressure  treatment,  the  cells
were allowed to settle down in an incubator at 37 °C with 5%
CO2/95% air for a period of 18–24 h unless stated otherwise.
The plates were subjected to trypsin treatment for 10 min and
centrifuged at 10,000x g for 10 min. The cells were collected
and resuspended in 10 µl of 1X phosphate buffered saline
(PBS) and added to 25 µl of lysis buffer (25 mM Tris pH 7.5,
100 mM sodium chloride [NaCl], 5 mM dithiothreitol [DTT],
1 µl of 50 mM disodium hydrogen phosphate [Na2HPO4], 1 µl
of 1 mM diethylenetriaminepentaacetic acid [DTPA], 1 µl of
100 µM butylated hydroxy toluene [BHT] and 10% sodium
dodecyl  sulfate  [SDS]).  The  cells  were  then  subjected  to
vortexing for 1 min, boiled, and used immediately or stored at
−20 °C for future use.
Western  analyses:  Protein  was  quantified  using  the
biochinchonic  acid  (BCA)  protein  assay  (Pierce
Biotechnology Inc., Rockford, IL). Western blot analysis was
performed with 25 µg of protein on 4%–20% Tris-glycine gels
(Invitrogen  Inc.).  After  fractionation,  the  proteins  were
electroblotted  onto  a  polyvinylidene  fluoride  (PVDF)
membrane  (Millipore,  Billerica,  MA)  using  standard
procedures and probed with the rabbit polyclonal iso[4]LGE2
protein adduct antibody. The characterization of iso[4]LGE2
protein adduct antibody has been described in detail in a
previous report [49].
Enzyme-linked immunosorbent assay: About 5 µg of purified
bovine serum albumin (BSA) or 10 µg of astrocyte lysate was
centrifuged at 10,000x g for 10 min, and the resulting clear
solution was transferred, placed in individual wells in a plate
(Costar 9018 plate; eBioscience, Inc., San Diego, CA), and
incubated for 20 min at room temperature. The supernatant
was discarded, and the plate was washed with PBS. The plates
were blocked with 1% ovalbumin for 1 h, washed with PBS,
and incubated for 1 h with rabbit polyclonal antibody against
iso[4]LGE2  protein  adduct.  After  subsequent  washes  with
PBS,  plates  were  incubated  with  the  secondary  antibody
coupled with alkaline phosphatase for 1 h, washed with PBS,
and incubated with phosphatase substrate (100 µl/well) in
diethanolamine  buffer,  pH  7.5.  The  absorbance  was  then
measured at 405 nm on a plate reader. The results of the
enzyme-linked immunosorbent assay (ELISA) analysis are
expressed as mean±standard error of the mean. Statistical
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point shown, was compared to 0.0 using the two tailed one-
sample t-test, and was found significantly different from 0.0
at each time point by the one-sample t-test (*p<0.05). The
asterisk indicates that the p value is less than 0.05.
Immunoprecipitation: About 3,000 astrocytes were placed in
100 µl of lysis buffer (1X PBS with 0.1% Genapol). The cells
were lysed by subjecting them to two cycles of freeze–thaw at
−80 °C and 37 °C, respectively. The protein concentration of
the  lysate  was  determined  using  the  BCA  assay  method
described above. About 50 μl of protein A beads were coupled
with 10 μg of the iso[4]LGE2 protein adduct antibody using
20  mg  of  dimethyl  pimelimidate  following  suitable
modifications  of  established  protocols  [50].  The  antibody
coupled beads were prewashed with 500 µl of lysis buffer,
subsequently incubated with 50 µl of cell lysate (~100 µg
protein) in a total volume of 250 µl, and then allowed to
incubate overnight at 4 °C. After washing the beads three
times with 500 µl lysis buffer, the products were eluted from
the beads with 30 µl of 100 mM glycine, pH 3.0. The eluents
were added to 5 µl of Laemmli buffer, boiled for 1 min, and
then separated over a 4%–20% gradient gel. The gels were
fixed with a 4:5:1 ratio of methanol:water:acetic acid, washed
with distilled water, and subsequently stained with Gel Code
Blue solution (Pierce Biotechnology Inc., Rockford, IL). The
control as well as the 25 mmHg and 100 mmHg treated cells
were subjected to anti-iso[4]LGE2 protein adduct and SDS–
PAGE  separation.  The  proteins  bands  were  subsequently
excised, in-gel trypsin digested, and subjected to tandem mass
spectrometry.
Treatment with pyridoxamine: In an effort to block protein
modification by the lipid peroxidation product iso[4]LGE2,
pressure-treated astrocytes were subjected to incubation in the
presence of pyridoxamine, an inhibitor of the isolevuglandin
protein  adduct  and  of  advanced  glycation  end  product
formation [42]. The experiment was performed using a range
of pyridoxamine concentrations (5–50 mM) to observe the
changes in isolevuglandin modification of proteins. Control
astrocytes  were  those  not  subjected  to  either  pressure  or
treatment with pyridoxamine. About 3,000 astrocytes were
plated on 15 mm plates and grown overnight in DMEM at
37 °C. Cells grown overnight were treated with pyridoxamine
(Sigma  Chemical  Co.)  in  4  ml  DMEM  so  that  the  final
pyridoxamine  concentration  reached  5  mM,  15  mM,  or
50 mM. These cells were incubated with pyridoxamine before
pressure treatment and after being subjected to 100 mmHg
pressure for 3 h. All pressure-treated cells were incubated at
atmospheric pressure for 16 h at 37 °C for post pressure
recovery. The cells were subjected to lysis by placing them
into 100 µl of lysis buffer (1X PBS and 0.1% Genapol) and
subjecting them to two freeze–thaw cycles at −80 °C and
37 °C, respectively. After centrifugation at 10,000x g for 10
min,  the  cell  lysates  were  subjected  to  SDS–PAGE
fractionation and western blot analysis with rabbit polyclonal
anti-iso[4]LGE2 protein adduct.
Cytochemical  analysis  and  microscopic  imaging:  The
isolated astrocytes were allowed to settle overnight at 37 °C
at atmospheric pressure on coverslips placed in a 15 mm
culture dish containing DMEM. For pressure treatment, the
plates  were  placed  in  the  pressure  chamber  at  a  specific
pressure  for  a  given  duration  specified  for  individual
experiments.  Following  incubation,  they  were  placed  for
recovery in the incubator at 37 °C and at atmospheric pressure.
After recovery, cells were fixed for 30 min in 100 μl of 4%
paraformaldehyde in PBS (pH 7.5) and were washed using
100 μl of 1X PBS (pH 7.5), which contained 80 μl of 0.2%
Triton X-100 for 30 min. The cells were incubated with mouse
monoclonal  antibody  against  GFAP  (1:200  dilution)  and
rabbit  polyclonal  anti-iso[4]LGE2  (1:200  dilution)  [49]
overnight at 4 °C. The secondary antibodies, anti-mouse and
anti-rabbit, were coupled with Alexa 488 and Alexa 594,
respectively.  Following  incubation  with  secondary
antibodies,  the  cells  were  stained  with  4',6-diamidino-2-
phenylindole (DAPI) for 45 min. Astrocytes were also stained
with phalloidin to observe changes in the actin filaments. For
Figure  2.  Increased  iso[4]LGE2
modification  of  proteins  in  astrocytes
from glaucomatous optic nerve head. A
representative western blot analysis is
shown of total protein lysates (25 µg)
from astrocytes derived from the human
optic nerve head. Age and gender of the
donors (all Caucasian individuals) have
been depicted. A was probed with rabbit
polyclonal  antibodies  to  iso[4]LGE2–
protein  adduct,  and  B  was  re-probed
with  mouse  monoclonal  antibody  to
GAPDH.
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1082this purpose, the pressure-treated and the untreated control
cells were fixed and permeabilized using 0.1% Triton X-100
for  1  min.  The  cells  were  then  stained  with  rhodamine-
phalloidin (1:100 dilution in 1X PBS) for 5 min. Following
staining, the coverslips were inverted and placed on slides,
sealed with Vectashield (Vector Labs, Burlingame, CA) and
subjected to fluorescence microscopy on a Nikon microscope,
model EFD-3 (Diagnostic Instruments Inc., Sterling Heights,
MI).
RESULTS
Isolated  astrocytes  from  glaucomatous  cadaver  donors
showed  elevated  immunoreactivity  for  iso[4]LGE2  protein
adduct: Isolated astrocytes derived from the optic nerve head
of patients with POAG showed an increase in iso[4]LGE2
protein adduct immunoreactivity (Figure 2A) Two significant
bands with molecular weights (MWs) of ~35 and ~50 kDa
were observed to have modifications in the glaucomatous
optic  nerve  head  astrocytes.  A  total  of  10  glaucomatous
donors and six normal donors were probed for this study. All
glaucomatous donors had elevated iso[4]LGE2 protein adduct
immunoreactivity as shown in the representative blot for six
Caucasian donors of either gender (Figure 2A). All donors
were Caucasian except one glaucomatous Asian donor. This
is similar to the trabecular meshwork where a significant
increase in iso[4]LGE2 protein adduct immunoreactivity was
found in tissues from glaucomatous eyes [30,31].
Increased  pressure  induces  iso[4]LGE2  modifications  in
astrocytes: Glaucomatous individuals often possess elevated
IOP. In patients with POAG, the IOP can reach 23–25 mmHg
while  patients  with  pigmentary  and  other  secondary
glaucomas  often  show  higher  pressure.  In  extremely  rare
occasions, IOP may even reach 80 mmHg in individuals with
hypertension  and  glaucoma.  In  traumatic  brain  injuries,
especially from blasts, astrocytes could be exposed to very
high  pressures  [16,51].  We  examined  whether  astrocytes
exposed  to  increased  pressure  develop  lipid  peroxidation-
derived  protein  modifications.  Isolated  astrocytes  were
subjected to pressures ranging from 25−150 mmHg for 3 h
and then allowed to settle for a period of about 16 h. Western
blot analysis of cell lysates revealed that pressures of 150
mmHg and greater resulted in iso[4]LGE2 modifications of
proteins  with  MWs  of  50  kDa  and  65  kDa  (Figure  3F).
Interestingly, lower pressures of 25–100 mmHg lead to a loss
of iso[4]LGE2 modifications in proteins with an apparent MW
of 35 kDa. Phalloidin staining of actin filaments shows no
obvious morphological changes following pressures up to 150
mmHg  (Figure  3A-E).  Surprisingly,  ELISA  analyses
designed to detect total iso[4]LGE2 immunoreactivity showed
an increase in total iso[4]LGE2 immunoreactivity in pressure-
treated astrocytes (Figure 4A). We reconciled the apparent
discrepancy between the two data sets (Figure 3F and Figure
4A)  to  non-homogenous  modification  of  proteins  in  this
pressure range. Thus, although total modification is unaltered
or may be slightly elevated as revealed by ELISA (Figure 4A),
there  was  a  lack  of  homogeneous  modification  eluding
western blot detection in this pressure range when exposed for
3  h  followed  by  a  16  h  recovery  period.  The
immunohistochemical detection of iso[4]LGE2 protein adduct
Figure  3.  Analyses  of  astrocytes
subjected  to  pressure.  Representative
fluorescence  microscopic  images  of
astrocytes  are  shown.  About  3,000
isolated rat brain cortex astrocytes were
subjected to pressures. Astrocytes were
stained  with  rhodamine-phalloidin  to
determine  the  integrity  of  the  actin
cytoskeleton  after  3  h  of  pressure
treatment at the indicated pressure and a
following 16 h recovery period: control
cells  (A)  without  pressure  treatment,
cells subjected to 25 mmHg (B), cells
subjected to 100 mmHg (C), and cells
subjected to 150 mmHg (D). All these
cells  were  subjected  to  fluorescence
microscopy  with  iso[4]LGE2–protein
adduct antibody after pressure treatment
and control cells that did not go through
any pressure treatment. E: Western blot
analysis for iso[4]LGE2 modification is
displayed. Astrocytes were subjected to
pressures (25–150 mmHg) for a period
of 3 h at 37 °C. Bottom panel was probed
with anti-GAPDH antibody.
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1083immunoreactivity in 100 mmHg-treated astrocytes compared
to controls (Figure 4B,C) was consistent with ELISA results.
Immunoprecipitation of total protein lysates exposed to 25
and 100 mmHg with an antibody to iso[4]LGE2 protein adduct
and subsequent mass spectrometry identified several potential
iso[4]LGE2-modified proteins that are involved in various
cellular processes (Table 1). All proteins identified in Table 1
were  obtained  as  a  result  of  two  independent
immunoprecipitation (IP) experiments.
Increased  iso[4]LGE2  protein  modification  in  astrocytes
exposed to high pressures for longer durations: Patients with
glaucoma often suffer extended periods of high intraocular
pressure.  To  determine  if  the  increase  in  iso[4]LGE2
modifications of astrocyte proteins correlated directly with
duration of pressure exposure, astrocytes were subjected to
extended periods of hydrostatic pressure. Application of 100
mmHg  on  astrocytes  for  a  period  of  3  h−33  h  showed  a
significant increase in iso[4]LGE2 immunoreactivity (Figure
Figure  4.  Analyses  of  astrocytes
subjected to pressure for iso[4]LGE2–
protein  adduct  formation.  A:  ELISA
analysis was performed with antibodies
to iso[4]LGE2–protein adduct and 10
µg of the control and pressure-treated
astrocyte  lysate  (described  in  greater
detail in Methods). Following pressure
treatment,  the  culture  medium  was
immediately  replaced  with  fresh
medium, and the cells were incubated at
37 °C for 16 h at atmospheric pressure.
Immunocytochemical  analysis  with
iso[4]LGE2–protein  adduct  antibody
was carried out for control cells (B) and
for astrocytes (C) that were subjected to
3 h of pressure at 100 mmHg and then
subsequently  subjected  to  a  recovery
period of 16 h.
TABLE 1. IDENTIFICATION OF PROTEINS AFTER ANTI-ISO[4]LGE2 IMMUNOPRECIPITATION.
Accession
 number*  Description
Peptide
matches
 MW
 (Da)
P11844 Gamma crystallin A 2 20,877
P02511 Alpha-crystallin B chain 2 20,159
P53672 Beta crystallin A2 2 22,096
P30154 Serine/threonine protein phosphatase 2A 2 66,183
P02489 Alpha-crystallin A chain 2 19,909
P01730 T-cell surface glycoprotein CD4 2 51,111
Q04759 Protein kinase C, theta type 2 81,847
P01236 Prolactin 2 25,876
P02746 Complement C1q subcomponent 2 26,441
P01137 Transforming growth factor beta-1 2 44,341
Q2L1Q8 MHC class II antigen 2 28,166
Q01094 Transcription factor E2F1 2 46,920
B1ALM2 Calcium channel, voltage-dependent 2 212,350
P11511 Cytochrome P450 19A1 2 57,883
P54687 Branched-chain-amino-acid aminotransferase, cytosolid 2 42,934
P03956 Interstitial collagenase 2 54,007
Q6Y4Q7 Tumor necrosis factor receptor superfamily member 1A 2 4,697
Q92674 Leucine-rich primary response protein 1 2 86,699
Q14830 Serine/threonine protein phosphatase with EF-hands-2 2 86,413
Q02779 Mitogen-activated protein kinase 10 2 103,605
Q9UHL4 Dipeptidyl-peptidase II precursor 2 54,309
The asterisk indicates that the column displays SWISS-PROT   accession numbers of identified proteins. Astrocytes were
subjected to pressure treatment for 4 h at 100 mmHg. Proteins from these astrocytes were identified by mass spectrometry.
Proteins that were identified in at least two independent experiments have been presented.
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10845A). The cells were allowed to incubate at 37 °C overnight for
about 16 h after pressure treatment for these experiments.
Effect of post pressure recovery period on astrocytes and
prophylaxis  against  protein  modification  by  endogenous
iso[4]LGE2:  Glaucomatous  as  well  as  normal  eyes  often
suffer from bouts of diurnal fluctuation in pressure, and often
the pressure drops to a lower boundary spontaneously. To
determine  the  changes  in  iso[4]LGE2  protein  adduct
immunoreactivity that occur during these periodic changes in
pressure, we examined iso[4]LGE2 protein modifications in
astrocytes that were subjected to a pressure of 100 mmHg for
3 h and allowed to recover for various periods (Figure 5B).
Control cells were incubated for similar periods but without
any pressure treatment. A representative control where cells
were  incubated  for  five  days  is  shown  (Figure  5B).  In
cytochemical analysis, the pressure-treated astrocytes showed
elevated  levels  of  iso[4]LGE2  protein  adduct
immunoreactivity  compared  to  controls  (Figure  4B,C).
Western blot analysis showed the presence of iso[4]LGE2
protein  adduct  immunoreactivity  for  relatively  higher
molecular weight proteins even 10 days after initial pressure
treatment  compared  to  controls  (Figure  5B).  This  data
Figure  5.  Western  blot  analyses  of
protein  extracts  from  astrocytes.  A
representative  figure  from  three
repeating  experiments  is  shown.  A:
Analysis is shown of protein extracts
from  rat  brain  cortex  astrocytes  that
were subjected to different durations of
pressure. Control cells were allowed to
remain in the incubator at 37 °C without
being  exposed  to  any  increase  in
pressure.  Other  astrocytes  were
subjected  to  an  increase  in  pressure.
Cells were subjected to fixed pressure
and  then  analyzed  for  iso[4]LGE2–
protein  modification.  About  3,000
isolated rat brain cortex astrocytes were
subjected to a pressure of 100 mmHg for
different time periods (ranging from 3–
33 h). Following pressure treatment, the
culture  medium  was  immediately
replaced  with  fresh  medium,  and  the
cells were incubated at 37 °C for 16 h at
atmospheric pressure. B: Western blot
analysis  is  shown  of  protein  extracts
from astrocytes that were subjected to
different post pressure recovery periods
for  iso[4]LGE2  modification.  About
3,000 isolated rat brain cortex astrocytes
were  subjected  to  a  pressure  of
100 mmHg for a period of 3 h and were
then  allowed  to  recover  at  37  °C.
Following  pressure  treatment,  the
culture  medium  was  immediately
replaced  with  fresh  medium,  and  the
cells were incubated at 37 °C for varying
periods  (ranging  from  1–10  days)  at
atmospheric  pressure.  Western  blot
analysis  was  performed  using  rabbit
polyclonal  antibody  to  iso[4]LGE2–
protein adduct after fractionation of total
cell lysates (25 μg protein lysate was
loaded in each lane) on 4%–20% SDS–
PAGE  and  transfer  to  a  PVDF
membrane. In A and B, bottom panels
were  probed  with  anti-GAPDH  as
indicated.
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1085indicates that the apparent generation of iso[4]LGE2 protein
modifications occurs and continues to increase for many days
after  initial  pressure  treatment.  Prior  incubation  with
pyridoxamine before being subjected to pressure did not show
a significant effect on iso[4]LGE2 immunoreactivity. Post
pressure  treatment  with  pyridoxamine  did  decrease  the
formation of iso[4]LGE2-modified proteins (Figure 6).
DISCUSSION
In the present study, we subjected astrocytes to a pressure of
100  mmHg  for  a  period  of  3  h  for  several  reasons.  This
pressure is easy to manage in a pressure chamber, and this
pressure and the duration did not lead to any discernable
changes  in  the  medium  pH  or  its  oxygen  levels  during
incubation  [52].  A  similar  device  have  been  used  for
hydrostatic pressure experiments by several investigators for
astrocytes [44,53,54] as well as for RGC5 cell lines [55,56].
Astrocytes  are  generators  of  arachidonic  and
docosahexaenoic acids [41] in the brain and the optic nerve
[24] and have been known to produce induced nitric oxide
synthase (iNOS) within 12 h of being subjected to hydrostatic
pressure [39]. Nitric oxide can also combine with superoxide
to produce peroxynitrite, which can cause a large number of
changes to proteins and lipids in vivo [57]. We now find that
pressure-treated cells showed greater amounts of iso[4]LGE2
protein  modifications  than  control  cells  as  revealed  by
fluorescence  microscopy  (Figure  4B,C).  The  iso[4]LGE2
modification of proteins in response to pressure treatment is
preventable by pharmacological intervention (Figure 6) or by
long-term  pressure  withdrawal.  However,  short-term
withdrawal is not very effective (Figure 5B). Whether or not
Figure  6.  Western  blot  analyses  for
determining  iso[4]LGE2-modification
of proteins in extracts from astrocytes
treated with pyridoxamine. About 3,000
isolated rat brain cortex astrocytes were
treated with freshly prepared 5–50 mM
pyridoxamine  (except  for  the  control
sample)  in  water  as  indicated.
Astrocytes were subjected to treatment
with  pyridoxamine  before  or  after
pressure treatment (100 mmHg for 4 h
followed by a recovery period of 16 h at
37  °C  and  at  atmospheric  pressure).
Western  blot  analysis  was  performed
with  iso[4]LGE2–protein  adduct
antibody after the transfer of 25 µg of
total  protein  extracts  onto  a  PVDF
membrane.  Bottom  panel  shows
probing with anti-GAPDH antibody.
Figure 7. Schematic representation of phospholipids with different ClogP values, membrane-sequestered IsoPG endoperoxides, and the hydrate
of iso[4]LGE2. Previous studies of phospholipid conformations in membranes showed that sn-2 acyl groups whose methyl esters have ClogP
of less than 2 protrude into the aqueous phase whereas with ClogP greater than 5, they are buried in the lipid bilayer. IsoPG endoperoxides
that are generated have been schematically shown (iso[4]PGH2 and iso[4]LGE2). They remain sequestered in membranes where they slowly
rearrange to isoLGs that become hydrated and protrude into the aqueous phase (iso[4]LGE2·H2O) allowing them to react with pyridoxamine
or proteins.
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1086such prophylaxis can be accomplished in vivo needs further
investigation.  Elevated  levels  of  oxidation  products  of
arachidonic  acid  such  as  iso[4]LGE2  were  found  in
glaucomatous TM when compared to control TM [30,31] and
in the optic nerve head astrocytes (Figure 2A). Previously,
another  lipid  oxidation  product,  4-hydroxynonenal,  was
shown to induce increased expression of antioxidant enzymes
in a dose-dependent manner in optic nerve head astrocytes
[58]. In vitro, an incremental increase in iso[4]LGE2 was
observed in response to 25–40 mmHg of pressure and again
beyond 100 mmHg of pressure (Figure 4A). This seems likely
to  be  of  significance  for  disease  pathology.  The  cellular
morphology  as  revealed  by  rhodamine-phalloidin  staining
appears not to undergo significant changes (Figure 3A-E). The
phalloidin staining undergoes a change in intensity between
50–100  mmHg  of  pressure  (Figure  3A-D).  Western  blot
analysis suggests a lack of specific iso[4]LGE2 protein adduct
immunoreactivity,  but  total  iso[4]LGE2  protein  adduct
immunoreactivity  between  these  pressures  remains
unchanged as revealed by ELISA analysis (Figure 3F and
Figure  4A).  The  immunohistochemical  observation  of
elevated iso[4]LGE2 protein  adduct immunoreactivity in cells
subjected  to  100  mmHg  of  pressure  was  consistent  with
enlarged astrocytes upon being subjected to elevated pressure.
Astrocytes  subjected  to  external  stimuli  such  as  elevated
pressure or hypoxia become reactive. One feature of reactive
astrocytes is cell size enlargement [59,60]. An enlarged cell
will have an expansion of the cell membrane thus exposing
the  cell  membrane  lipids  to  the  oxidative  environment
commensurate  with  more  iso[4]LGE2  protein  adduct
immunoreactivity at the cell surface. The cells survive for a
prolonged period after pressure withdrawal (Figure 5B), i.e.,
a sufficiently long period of over 30 h. In our experiments, the
total packed volume of cells was less than 0.5 ml, and the
incubation volume was about 2 l (at least 4,000 fold more
compared  to  cell  volume).  However,  with  extended  time
duration in addition to pressure, hypoxia cannot be ruled out.
We determined the medium pH and oxygen content for up to
9 h of incubation. No significant changes were observed.
Western blot analysis provided evidence that pressure-treated
astrocytes  do  increase  production  of  the  specific  lipid
peroxidation  product,  iso[4]LGE2.  Western  blot  analysis
revealed that subjecting these cells to 100 mmHg of pressure
for 3 h leads to a small decrease in iso[4]LGE2 after a 16 h
recovery period when compared to untreated controls (Figure
5A). However, longer exposures to pressure leads to increased
iso[4]LGE2 immunoreactivity (Figure 5A), and the recovery
period also has a pronounced effect. Prolonged culture of
astrocytes  results  in  a  loss  of  baseline  iso[4]LGE2
immunoreactivity (data not shown). However, this loss is
much  less  pronounced  in  astrocytes  subjected  to  pressure
treatment (Figure 5B).
Analysis using mass spectrometry of proteins derived
from  pressure-treated  astrocytes  revealed  major  potential
protein targets of oxidative modification in astrocytes (Table
1).  Analysis  of  these  proteins  may  further  elucidate
mechanisms  of  pressure-induced  damage  and  consequent
dysfunction in astrocytes.
Two observations are especially noteworthy with respect
to  potential  therapeutic  interventions.  Generation  of
iso[4]LGE2 protein modifications is a slow process that occurs
after pressure has been applied and during the subsequent
recovery period, and iso[4]LGE2 can be efficiently trapped by
pyridoxamine  (vitamin  B6),  which  acts  as  a  sacrificial
nucleophile [42,61]. Thus, the application of pressure in the
absence of pyridoxamine and the subsequent treatment with
pyridoxamine  during  the  recovery  period  dramatically
reduced  protein  modification,  presumably  because
pyridoxamine competes effectively with proteins for binding
to isolevuglandins (isoLGs) as shown in Figure 1 [62-64].
Paradoxically,  we  found  that  the  presence  of
pyridoxamine  during  the  application  of  pressure  did  not
reduce  protein  modification  by  the  highly  reactive  γ-
ketoaldehyde  iso[4]LGE2,  which  occurred  during  the
subsequent recovery period. This behavior is understandable
if pyridoxamine is consumed by short-lived reactive oxygen
species (ROS) and a torrent of electrophilic lipid oxidation
products escaped from the lipid bilayer – where they are
generated  by  oxidative  cleavage  of  polyunsaturated  acyl
chains in membrane phospholipids – into the aqueous phase
where pyridoxamine resides [64].
Our predictions of the preferences for lipid oxidation
products to remain sequestered in the nonpolar interior of
membrane lipid bilayer versus being ejected into the aqueous
phase are based on previous 1H Nuclear magnetic Resonance
(NMR) nuclear Overhauser effect studies that established the
conformations of phosphatidylcholines with oxidized  sn-2
acyl  groups  [65,66].  Thus,  the  4-keto-2-Octene-dioic  acid
(KOdiA),  5-Oxovalerate  (OV),  and  9-Oxo-noanoate  (ON)
sn-2  acyl  groups  in  oxidatively  truncated
phosphatidylcholines adopt a conformation in which these
oxidized acyl groups protrude like whiskers from the lipid
bilayer into the aqueous phase while an sn-2 13-hydroxy-9,
11-octodecadienenoate (HODE) group remains buried in the
hydrophobic interior of the membrane (Figure 7). We now
note that sn-2 acyl groups whose methyl esters have octanol/
water  partition  coefficients,  ClogP<2,  protrude  into  the
aqueous phase whereas with ClogP>5, they are buried in the
lipid bilayer.
Because  they  are  hydrophilic,  some  lipid  oxidation
products such as malondialdehyde (MDA) with ClogP=−0.36
are expected to be ejected from the lipophilic interior of the
membrane,  which  is  where  they  are  generated,  into  the
aqueous phase. In the aqueous phase, they can react with
pyridoxamine that has ClogP=−0.81 (Figure 7) and remain
there (Figure 1). A previous study showed that levels of MDA
in the retina increase by an order of magnitude with a modest
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1087increase of IOP from a normal level of 14 mmHg to a modestly
elevated level of 24 mmHg induced by cauterization of three
episcleral veins in rats [67].
Lipid  oxidation  also  generates  prostaglandin
endoperoxide  isomers  such  as  iso[4]prostaglandin
endoperoxide  H  (PGH)2  that  subsequently  rearrange  to
isolevuglandins  such  as  iso[4]LGE2  by  a  non-oxidative
transformation that does not involve ROS. Even though the
levels of ROS rapidly decline after the initial oxidative insult,
the production of isoLGs can occur during the recovery period
because their precursors, e.g., iso[4]PGH2, are buried in the
lipophilic interior of the lipid bilayer where they very slowly
transform  into  isoLGs  (Figure  7).  Thus,  although
prostaglandin endoperoxides rearrange rapidly (t1/2 ~5 min) to
the γ-ketoaldehyde levuglandins in aqueous solution [68,69],
rearrangement of such endoperoxides in an aprotic lipophilic
environment is orders of magnitude slower [69]. The isoLGs
then form hydrates [68] that are expected to protrude from the
lipid bilayer into the aqueous phase where they can react with
proteins or pyridoxamine (Figure 1). This scenario presents
both a challenge and an opportunity to prevent pathological
protein modification by isoLGs. The challenge is to withstand
a  protracted  barrage  of  toxic  γ-ketoaldehydes  that  are
generated as a consequence of lipid oxidation. Their formation
cannot  be  prevented  with  antioxidants  applied  after  the
generation  of  endoperoxide  precursors  because  the
conversion of endoperoxides into isoLGs does not involve
oxidation. On the other hand, because their generation is slow,
there is ample time to intercept them after the oxidative insult,
and pyridoxamine is very effective in doing just that.
Subjecting astrocytes to hydrostatic pressure alters them
in a way that induces oxidative injury. Oxidative stress was
previously shown to be an early event in hydrostatic pressure-
induced retinal ganglion cell damage [55]. The nature of the
alteration remains to be determined, although disruption of
membrane  structures  resulting  in  leakage  [58]  between
cellular compartments is a potential contributor [70].
In  conclusion,  astrocytes  isolated  from  the  human
glaucomatous optic nerve head showed higher levels of lipid-
derived oxidative immunoreactivity associated with protein
modifications than that of the non-glaucomatous controls. In
isolated astrocytes, in vitro, the levels of modification increase
with  pressure.  This  pressure  effect  may  account  for  the
elevated  levels  of  isoLG-protein  modification  in
glaucomatous optic nerve head astrocytes compared to those
in the normal nerve head. Astrocytes apparently respond to
increased pressure by producing oxidation products of fatty
acids such as iso[4]LGE2. This highly reactive lipid covalently
adducts to proteins within seconds, leading to inter alia, which
is the formation of protein–protein cross-links. Rhodamine-
phalloidin staining revealed that astrocytes can tolerate a large
amount  of  pressure  and  yet  maintain  their  cytoskeletal
structure.  However,  the  cells  have  been  altered,  and
iso[4]LGE2 modification of astrocyte proteins evolves with
aging, favoring adducts of higher molecular weight, perhaps
owing  to  isoLG-induced  cross-linking.  The  ability  of
pyridoxamine  to  prevent  this  presumably  pathological
modification of proteins is a seminal discovery that seems
likely to have therapeutic utility for eye and brain pathology
consequent to cellular insult caused by pressure.
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